Document is current
Any future updates will be listed below
-
Authors
Brown, Jacques P.
Adachi, Jonathan D.
Schemitsch, Emil
Tarride, Jean-Eric
Brown, Vivien
Bell, Alan
Reiner, Maureen
Oliveira, Thiago
Motsepe-Ditshego, Ponda
Burke, Natasha
Slatkovska, Lubomira http://orcid.org/0000-0001-5027-7989
-
Funding
Funding for this research was provided by:
Amgen Canada
- License Information
-
More Information
Article History
Received: 15 May 2020
Accepted: 5 January 2021
First Online: 23 January 2021
Ethics approval and consent to participate
: The study protocol was approved by the Advarra Institutional Review Board. De-identified aggregate level data was provided from ICES following patient-level analysis.
: Not applicable.
: JPB has received consulting fees and honoraria from Amgen and Servier; received research funding from Mereo BioPharma, Radius Health and Servier; served on speakers’ bureau for Amgen. JDA has received consulting fees from Amgen and Eli Lilly; received research funding from Amgen, Pfizer, and BMS; served on the speakers’ bureau for Amgen; served on boards for the International Osteoporosis Foundation and Ontario Rheumatology Association. ES has received consulting fees from Amgen. J-ET has received consulting fees, research funding and honoraria from Allergan, AstraZeneca, Amgen, CSL Behring, Janssen, Novo Nordisk, Sage, Assurex/Myriad, Edwards Lifesciences, Pfizer, Roche, Merck, GlaxoSmithKline, Evidera, PCDI, CADTH. VB has received honoraria from Amgen and have served on Amgen Ad Boards. AB has received consulting fees, research funding and honoraria from Amgen, Bristol Myers Squibb, Janssen, AstraZeneca, Novartis, Pfizer, Bayer, Lilly, Boehringer Ingelheim, Sanofi, Valeant. LS, NB, PM-D, TO and MR are employees of and own stock in Amgen.
